Not just when something goes wrong, but consistently. Proactively. That means making it easy to access care that fits their everyday life, gets smarter over time, and can stay with them across years and decades.
Nearly 2.6M subscribers are now turning to us for that kind of access because they believe that the best care is simple, personal, and built for the long-term. And we believe this is just the beginning, as growth continues across the platform.
Here's what to know from today's Q1 results:
Our US business is building momentum.
As we introduce new specialties and shift our weight loss strategy to a globally unified approach, we’ve been able to provide access to the broadest possible assortment of innovative medicines, alongside the comprehensive experience that customers expect. In weight alone, the market has evolved dramatically since we entered it two years ago, and we’ve transformed our approach to match. We are seeing near record levels of adoption – within six weeks of introducing access to the full assortment of Novo’s GLP-1 products at self-pay prices, we’ve fulfilled more than 125K orders of Wegovy products. We believe that kind of result speaks to something more than distribution: it's proof that our customers come to us for the best available treatments and stay because of the quality and continuity of the experience we build around them.
Our growing global presence is becoming a key competitive advantage.
We’re rapidly becoming one of the world's largest consumer health platforms – and that scale is a strategic asset, not just a milestone. Our international business has grown to over $78M in revenue in the first quarter, growing nearly 10x year-over-year. We expect our planned acquisition of Eucalyptus to close in the second half of the year, which will extend our leadership position in consumer health across Australia, Canada, Germany, Japan and the UK. As we expand our footprint, we have the opportunity to impact hundreds of millions of people, broadening the network effects of our platform and becoming more valuable to the pharma, biotech, and diagnostic partners who increasingly rely on us to connect with people at scale.
We’re aiming to build deeper, more engaged, long-term relationships with our customers
{inline-gallery}
More and more, we see customers looking for access to truly proactive and continuous care, informed by health insights to help them get – and stay – healthy. We’ve prioritized investments that deepen our customer relationships and make it simpler for anyone to be more proactive about feeling their best. Our Testosterone offering, which is now serving tens of thousands of men, is showing what access to proactive, ongoing care can actually look like. Customers track their health over time through simple at-home blood tests, work with their providers to adjust treatment, and see real results: 95% of Hims customers relying on us for their testosterone support saw an increase in testosterone levels in just two months. That information layer allows our platform to evolve with our customers as their needs change.
We're investing in a platform that gets better as it gets bigger — and is becoming harder to replicate.
We’re leveraging data and technology to become an irreplaceable companion to our customers, and an incredibly valuable partner to other health innovators who want to reach – and hold onto – more customers. Over the past year, we have re-architected the platform around reusable, modular capabilities that can better serve our customers and providers across comprehensive end-to-end care, rather than a single condition at a time. We’ve also embedded intelligence across every step of the care journey – not to replace the clinician, but to make every interaction more informed, more timely, and more personal. Tools like our AI provider co-pilot and Labs AI allow us to understand each customer's full health profile and reach them proactively, while keeping independent providers responsible for all clinical decision making. Our advantage comes from powering the end-to-end experience across categories, and combined with our global presence, our dataset gets more powerful and harder to replicate.
These results reinforce our confidence in our 2030 targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. In an industry focused on reacting to illness, we're changing what people believe is possible: health that is simple, deeply personal, and built for everyday life.
Cautionary Note Regarding Forward-Looking Statements
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “plans,” “assumes,” “may,” “will,” “likely,” “potential,” “projects,” “predicts,” “continue,” “goal,” “strategy,” “future,” “forecast,” “target,” “outlook,” “opportunity,” “confidence,” “foundation,” “groundwork,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line revenue growth and profitability and our ability to attain our 2026 and long-term financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, the markets accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; potential strategic investments, partnerships, or collaborations, and the expected timing or outcome of any such investments, partnerships, or collaborations; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, strategy, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions; changes in our product or offering mix, and the timing and market acceptance of any new products or offerings; the timing and anticipated effect of any pending or recently completed acquisitions; the success of our business model; our market opportunity; our ability to scale our business and expand internationally; the growth of certain of our specialties; our ability to innovate on and expand the scope of our offerings and experiences, including through the use of diagnostics, data analytics and artificial intelligence; our ability to reinvest into the customer experience; and our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions or statements in relation to any such legal and regulatory requirements. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this press release are based on our current expectations, assumptions, and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission (the “Commission”).
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this press release are made only as of May 11, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.
